IMM0306

Phase 3Small molecule

IImmuneOnco Biopharmaceuticals (Shanghai) Inc.

IMM0306 is one of 67 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Follicular LymphomaActive, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Follicular LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

IMM0306

IImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 3

2 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Tafasitamab

Incyte

Preclinical

7 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Not yet recruiting

Follicular Lymphoma

NCT07355283

Clinical

Trials by Indication[1]

Lymphoma2 trials

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Unknown status·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1/2·NCT05805943·154 enrolled

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

Suspended·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1·NCT04746131·90 enrolled

Lenalidomide1 trial

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Unknown status·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1/2·NCT05771883·102 enrolled

Follicular Lymphoma1 trial

IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma

Not yet recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 3·NCT07355283·198 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for IMM0306. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMM0306 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMM0306. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmuneOnco Biopharmaceuticals (Shanghai) Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IImmuneOnco Biopharmaceuticals (Shanghai) Inc.

IMM0306

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Lymphoma2 trials

Lenalidomide1 trial

Follicular Lymphoma1 trial

References

Drug Info

Quick Facts

Related News